Follicular Lymphoma (FL)

Follicular lymphoma (FL) accounts for the vast majority of indolent non-Hodgkin's lymphomas (NHLs).1

  • In 2014, there were an estimated 661,996 people living with NHL in the United States3
  • FL is the second most common subtype of NHL, representing about 20% of NHLs3
  • The median age at diagnosis of FL patients in the United States is 60 years3

Advances in the understanding of the disease biology, diagnostic and prognostic indicators, and treatment options have improved the outlook for FL patients.4

  • Although not curable in the vast majority of patients, FL typically can be managed over time5

References

  1. Friedberg JW. Treatment of follicular non-Hodgkin's lymphoma: the old and the new. Semin Hematol. 2008;45(3 suppl 2):S2-S6. doi:10:1053/j.seminhematol.2008.07.003.
  2. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma. NHL. Bethesda, MD: National Cancer Institute. https://seer.cancer.gov/statfacts/html/nhl.html. Updated April 2017. Accessed August 23, 2017.
  3. Freedman AS, Friedberg JW, Mauch PM, Dalla-Favera R, Harris NL. Follicular lymphoma. In: Armitage JO, Mauch PM, Harris NL, Coiffier B, Dalla-Favera R, eds. Non-Hodgkin Lymphomas. 2nd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:266-283.
  4. Hagenbeek A. Maintenance or eradication of residual disease in indolent lymphoma: where do we stand? J Clin Oncol. 2009;27:1540-1542.
  5. Hiddemann W, Cheson BD. How we manage follicular lymphoma. Leukemia. 2014;28:1388-1395.